Yüklüyor......
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma
ZUMA-1 demonstrated a high rate of durable response and a manageable safety profile with axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in patients with refractory large B-cell lymphoma. As previously reported, prespecified clinical covariates for sec...
Kaydedildi:
| Yayımlandı: | Blood Adv |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
American Society of Hematology
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7556133/ https://ncbi.nlm.nih.gov/pubmed/33035333 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002394 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|